IDEAS home Printed from https://ideas.repec.org/h/spr/sprchp/978-1-4757-3466-9_8.html
   My bibliography  Save this book chapter

Design and Analysis of Phase I Trials in Clinical Oncology

In: Applied Statistics in the Pharmaceutical Industry

Author

Listed:
  • Axel Benner

    (German Cancer Research Center, Biostatistics Unit)

  • Lutz Edler

    (German Cancer Research Center, Biostatistics Unit)

  • Gernot Hartung

    (Mannheim Medical School, Oncological Center)

Abstract

In oncology the Phase I trial is the first occasion to treat cancer patients experimentally with a new drug with the aim of determining the drug treatment’s toxic properties, characterizing its dose-limiting toxicity (DLT), and estimating a maximum tolerable dose (MTD) as a benchmark dose for further clinical trials. Phase I trials are usually accompanied by an elaborate clinical pharmacology and the determination of individual pharmacokinetic parameters. Additionally, there is high interest in screening the drug for early signs of antitumor activity (Von Hoff et al., 1984). At this stage of drug development, a safe and efficacious dose in humans is unknown and information is available only from pre-clinical in vitro and in vivo studies. Therefore, patients are treated successively and in small groups, beginning at a low dose very likely to be safe (starting dose), and escalating progressively to higher doses until drug-related toxicity manifests and reaches DLT. Doses which induce a predetermined frequency of DLT among the patients treated, define the MTD (Bodey and Legha, 1987).

Suggested Citation

  • Axel Benner & Lutz Edler & Gernot Hartung, 2001. "Design and Analysis of Phase I Trials in Clinical Oncology," Springer Books, in: Steven P. Millard & Andreas Krause (ed.), Applied Statistics in the Pharmaceutical Industry, chapter 8, pages 189-216, Springer.
    • Handle: RePEc:spr:sprchp:978-1-4757-3466-9_8
    DOI: 10.1007/978-1-4757-3466-9_8
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a
    for a similarly titled item that would be available.

    More about this item

    Keywords

    ;
    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:sprchp:978-1-4757-3466-9_8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.